New medicines do not reach patients through a positive scientific opinion alone. Between a recommendation, formal authorisation and real availability lie launch planning, pricing and reimbursement, reliable product data, inventory design, training and a qualified supply chain. The CHMP recommendations from summer 2026 therefore show both therapeutic progress and the operational work behind a successful launch.
A CHMP recommendation is not yet the final EU authorisation
The European Medicines Agency’s Committee for Medicinal Products for Human Use assesses quality, efficacy and safety. A positive opinion normally forms the basis for the subsequent decision by the European Commission. National steps then follow before broad supply. Pharmacies, wholesalers, manufacturers and logistics partners nevertheless need to prepare much earlier.
Across June and July 2026, 18 new medicines received positive recommendations. They cover cardiovascular and metabolic disease, dermatology, ophthalmology, rare diseases, vaccines, diabetes and Parkinson’s disease. Tablets, injections, vaccines and implants each create distinct requirements for data, storage, distribution and counselling.
July 2026: new treatment options and new supply processes
For lipid disorders, Lyrokaul (lerodalcibep), Evlarco (obicetrapib/ezetimibe) and Ubeslo (obicetrapib) received positive opinions. Their active substances, combinations and modes of use differ. Product master data, prescribing information, pack variants and counselling content must therefore be clearly separated in operational systems.
Susvimo (ranibizumab), a refillable ocular implant, introduces a particularly process-intensive pathway. Specialist administration, appointment planning, availability, traceability and coordination between clinic, procurement and logistics are all relevant. Icotyde (icotrokinra) adds an oral approach for plaque psoriasis, while Lynavoy (linerixibat) targets cholestatic pruritus in primary biliary cholangitis.
Other positive recommendations covered Nezglyal (leriglitazone), Zokovea (ensitrelvir), the biosimilar Cavoley (pegfilgrastim) and the generics Riociguat Accord, Ruxolitinib Viatris and Tafamidis Accord. Eight additional opinions extended existing indications, creating simultaneous launches, range changes and new demand patterns.
June 2026: vaccine, Parkinson’s disease, diabetes and rare conditions
Six new medicines received positive opinions in June: Aujemflu, an influenza vaccine for adults aged 50 and over; Hopledo (levodopa/carbidopa) for Parkinson’s disease with motor fluctuations; and Onswik (insulin efsitora alfa) for type 2 diabetes. Daybu (trofinetide) addresses Rett syndrome from five years of age. The list also includes the biosimilars Denosumab Ascend (denosumab) and Nylaspeg (pegfilgrastim).
Twelve recommended indication extensions covered vaccines, oncology, dermatology and rare diseases. Operationally, an extension can change demand, training requirements, stock policy, eligible age groups, documentation and reimbursement routes.
Medicine and active-substance index, summer 2026
The direct index links to each medicine and active substance. The products are listed at CHMP-opinion stage; the subsequently approved product information governs use, storage and distribution.
Lyrokaul – lerodalcibep
A monthly self-administered injection for lipid disorders; launch planning must align dosage form, patient support and final storage requirements.
Evlarco – obicetrapib/ezetimibe
An oral combination for lipid disorders that must remain clearly separated from obicetrapib monotherapy in data and counselling.
Ubeslo – obicetrapib
Oral obicetrapib monotherapy requiring unambiguous item and prescribing data.
Susvimo – ranibizumab
A refillable ocular implant whose specialist administration links appointment planning, release status and traceability.
Icotyde – icotrokinra
An oral IL-23 receptor approach for plaque psoriasis; approved age, weight and product details belong in operational data and counselling.
Nezglyal – leriglitazone
An exceptional-circumstances recommendation for cerebral adrenoleukodystrophy; small patient numbers require controlled case-based supply.
Zokovea – ensitrelvir
An antiviral option for COVID-19 post-exposure prophylaxis where readiness for short-term demand peaks matters.
Cavoley – pegfilgrastim
A biosimilar for neutropenia reduction requiring reliable identity, batch, serialisation and substitution data.
Riociguat Accord – riociguat
A generic for pulmonary hypertension requiring accurate indication, population, strength and pack mapping.
Ruxolitinib Viatris – ruxolitinib
A generic covering several haematological indications whose product and indication data require controlled versioning.
Tafamidis Accord – tafamidis
A generic for hereditary transthyretin amyloidosis with cardiomyopathy, requiring dependable specialised supply.
Aujemflu – inactivated influenza surface antigens
An influenza vaccine for adults aged 50 and over; seasonal forecasts, qualified temperature control and vaccine procurement must align.
Hopledo – levodopa/carbidopa
A Parkinson's option for motor fluctuations requiring specialist product and supply information.
Onswik – insulin efsitora alfa
An insulin for adults with type 2 diabetes whose approved temperature and handover conditions determine the supply process.
Daybu – trofinetide
A re-examined option for neurobehavioural symptoms of Rett syndrome from age five; the rare indication affects demand and availability planning.
Denosumab Ascend – denosumab
A biosimilar for bone complications and giant-cell tumour of bone requiring complete batch- and product-specific quality data.
Nylaspeg – pegfilgrastim
A biosimilar for reducing neutropenia duration that must remain distinct from other pegfilgrastim products in data and procurement.
What pharmacies should prepare
- Structure product knowledge: incorporate use, dosage form, target population, handling and counselling needs into training and the QMS.
- Check master data: new items, packs, identifiers, storage instructions and order routes must be complete and consistent.
- Define supply pathways: specialist products may need a dedicated ordering, handover or clinic process.
- Separate substitution decisions: originators, biosimilars and generics require correct professional and legal classification.
- Plan patient communication: recommendation, authorisation, launch and actual availability must not be presented as identical milestones.
Wholesale and logistics: launch readiness matters
Before the first order, a new medicine must pass through item setup, regulatory attributes, storage zoning, temperature classification, serialisation, dangerous-goods checks, returns, complaints, service levels and contingency planning. Errors at this stage later become false stock, delivery delays or manual clarification.
Temperature-controlled or time-critical products add packaging qualification, monitoring, seasonal risk assessment and defined deviation decisions. Implants and specialist dosage forms often require closer alignment with clinic workflows. Wholesale therefore acts as an information and coordination hub, not merely a distributor of boxes.
Why logistics for new medicines can be unusually complex
The final requirements always follow the approved product information and the qualified distribution strategy. Before launch, however, companies already need to control several connected risks:
- Temperature and time: controlled room temperature, 2–8 °C, possible frozen ranges, maximum journey time and excursion limits must remain secure at every handover.
- Packaging and lanes: summer and winter profiles, transit time, customs and hub risks and the last mile require qualified packaging and reliable transport lanes.
- Traceability: batch, expiry, serialisation, consignee and temperature records must support recalls, complaints and deviation assessment without data gaps.
- Small volumes and high value: orphan medicines, implants and specialist products often combine uncertain demand with substantial inventory and failure risk.
- Clinical appointment dependency: specialist medicines must reach the treatment site on time and in a releasable condition; a late or quarantined shipment may interrupt the entire care pathway.
- Returns and deviations: returned products cannot automatically re-enter saleable stock. Quarantine, data review, quality decisions and CAPA must be predefined.
- Cross-border supply: labelling, market status, language, wholesale authorisations, GDP responsibilities and import routes differ. An EU authorisation does not replace national launch and distribution planning.
The key question is therefore not merely whether a provider can move a parcel, but whether quality, data, ownership and escalation are controlled across the entire chain.
Six steps for a robust medicine launch
- document regulatory status separately from the planned launch date,
- approve complete product, pack and logistics master data,
- model demand and inventory risk by indication and channel,
- qualify storage, transport and handover conditions,
- prepare pharmacies and customer service with aligned professional information,
- monitor availability, deviations and feedback closely after launch.
tiger.PHARMA perspective and services
tiger.PHARMA connects market access, pharmacy practice, pharmaceutical wholesale and GDP logistics in one end-to-end launch process. Our strength lies at the interfaces: translating product requirements into workable warehouse, transport, data and pharmacy processes while considering supply reliability and economics together.
Depending on the project, tiger.PHARMA supports GDP gap analysis, risk-based distribution strategy, logistics requirements, partner assessment and audit readiness, quality agreements, SOPs, training and escalation routes. This can also include temperature mapping, packaging and transport qualification, lane-risk assessment, deviation and CAPA structures, returns and recalls, launch stock and contingency planning.
tiger.PHARMA does not replace the legally responsible regulatory or pharmaceutical functions. We help manufacturers, marketing-authorisation holders, wholesalers, logistics providers and pharmacies work together with clear requirements, verifiable data and robust procedures.
The aim is a controlled launch: the right medicine reaches care with demonstrably suitable storage, complete traceability and understandable counselling.
Official and authoritative sources
- European Medicines Agency: CHMP meeting highlights, 20–23 July 2026
- European Medicines Agency: CHMP meeting highlights, 22–25 June 2026
- European Commission: Union Register of medicinal products
- EUR-Lex: Guidelines on Good Distribution Practice for medicinal products
FAQ: new medicines and launch logistics
Is a positive CHMP opinion already an EU authorisation?
No. It is an important scientific step before the European Commission's decision. Launch, reimbursement and actual supply follow separate timelines.
Do all new medicines require refrigerated transport?
No. The approved requirements of the individual product apply. Products without refrigerated storage may still require controlled temperature, humidity or light protection or limited journey times.
When should logistics planning begin?
Early enough for data, partners, quality agreements, packaging, lanes, SOPs and training to be approved before the first commercial order. Critical lanes and seasonal profiles require additional lead time.
How can tiger.PHARMA help?
tiger.PHARMA structures requirements, assesses risks and partners, develops GDP-compliant processes and supports operational launch readiness from item setup to safe handover into care.
Review launch logistics: Explore temperature-controlled pharmaceutical logistics or discuss your medicine launch with tiger.PHARMA.